Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoStart with Pro — $79/mo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

Agios Pharmaceuticals, Inc.

Filed: Jun 18, 2026CIK: 0001439222
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Agios Pharmaceuticals stockholders approved an amendment to the 2023 Stock Incentive Plan on June 18, 2026, increasing available shares by 2,000,000 for equity compensation, signaling the company's commitment to employee retention and alignment with shareholder value creation.

Key Takeaways

2,000,000 additional shares authorized under the 2023 Stock Incentive Plan for employee compensation

Amendment includes specific provision for same increase in incentive stock options availability

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJun 18, 2026
Item5.02
CategoryExecutive Change
CIK0001439222
Accession #0001439222
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
stock offering

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings